Novavax Deal With Mabion Boosts Poland’s Nascent Biotech Scene
- Polish company will start trials, obtain vaccine technology
- Mabion shares surge a record 89% after the deal is announced
Novavax phase 3 Covid-19 clinical vaccine trials.
Photographer: Karen Ducey/Getty Images
This article is for subscribers only.
Poland’s fledgling biotechnology industry got an unexpected vote of confidence after Mabion SA won a deal with Novavax Inc. to potentially produce its future Covid-19 vaccine.
Mabion will start commercial-scale production trials of Novavax shot and obtain access to the U.S. company’s technology, according to an agreement unveiled on Wednesday. Shares in the Warsaw-listed biotech company soared a record 89%.